Analysts Issue Forecasts for QNCX FY2024 Earnings

Quince Therapeutics, Inc. (NASDAQ:QNCX) – Analysts at Brookline Capital Management issued their FY2024 earnings per share estimates for shares of Quince Therapeutics in a report released on Wednesday, December 18th. Brookline Capital Management analyst K. Raja anticipates that the company will earn ($1.21) per share for the year. Brookline Capital Management currently has a “Buy” rating and a $9.00 price target on the stock. Brookline Capital Management also issued estimates for Quince Therapeutics’ Q4 2024 earnings at ($0.19) EPS, FY2025 earnings at ($0.79) EPS, FY2026 earnings at ($0.69) EPS, FY2027 earnings at ($0.14) EPS and FY2028 earnings at $0.52 EPS.

A number of other brokerages have also recently weighed in on QNCX. EF Hutton Acquisition Co. I upgraded Quince Therapeutics to a “strong-buy” rating in a research report on Tuesday, October 22nd. Rodman & Renshaw started coverage on Quince Therapeutics in a report on Tuesday, October 29th. They issued a “buy” rating and a $11.00 price objective for the company. RODMAN&RENSHAW raised Quince Therapeutics to a “strong-buy” rating in a research note on Tuesday, October 29th. Finally, Maxim Group started coverage on Quince Therapeutics in a research note on Thursday, November 7th. They issued a “buy” rating and a $6.00 price target for the company. Three research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, Quince Therapeutics currently has a consensus rating of “Buy” and an average target price of $8.67.

Quince Therapeutics Trading Up 1.1 %

NASDAQ QNCX opened at $1.78 on Friday. The firm has a market capitalization of $78.32 million, a PE ratio of -1.44 and a beta of 0.74. Quince Therapeutics has a one year low of $0.51 and a one year high of $2.45. The company has a 50-day simple moving average of $1.61 and a 200-day simple moving average of $1.03. The company has a debt-to-equity ratio of 0.33, a quick ratio of 9.53 and a current ratio of 9.53.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Quince Therapeutics stock. Geode Capital Management LLC raised its position in shares of Quince Therapeutics, Inc. (NASDAQ:QNCX) by 24.2% in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 339,125 shares of the company’s stock after purchasing an additional 66,170 shares during the quarter. Geode Capital Management LLC owned about 0.78% of Quince Therapeutics worth $263,000 as of its most recent SEC filing. 30.75% of the stock is currently owned by institutional investors.

Quince Therapeutics Company Profile

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.